Modern effective means of topical therapy and skin care for patients with psoriasis
- Authors: Filimonkova N.N.1, Kokhan M.M.1
-
Affiliations:
- Ural Research Institute of Dermatovenereology and Immunopathology
- Issue: Vol 32, No 5 (2025)
- Pages: 129-134
- Section: Pharmacological properties of drugs
- URL: https://journals.rcsi.science/2073-4034/article/view/316502
- DOI: https://doi.org/10.18565/pharmateca.2025.5.129-134
- ID: 316502
Cite item
Abstract
The problem of topical therapy for patients with chronic dermatoses remains relevant in modern dermatology, despite a significant number of research works. The creation of new combined skin care products for patients with psoriasis allows potentiating the effect of most drugs in the absence of side effects in the form of allergic reactions, drug dependence and effects on other organs.
Psoriasis in approximately 80% of patients manifests itself in a mild or moderate degree and is initially treated with local (topical) therapy. In the spectrum of topical therapy, glucocorticosteroids, betamethasone/calcipotriol, vitamin D3 analogues are effective.
The domestic company Pharmtec has created a series of care products: Depsoriol® cream and lotion for patients suffering from vulgar psoriasis, including lesions of the scalp. In the study, when using this drug simultaneously with leading topical therapy products, or with subsequent care, a more rapid achievement of the clinical effect, positive dynamics of the psoriasis area and severity index (PASI) and the dermatological quality of life index (DQLI), compared with other skin care products, and the absence of side effects were noted.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Nina N. Filimonkova
Ural Research Institute of Dermatovenereology and Immunopathology
Email: nnfil2008@mail.ru
ORCID iD: 0000-0003-2872-3836
SPIN-code: 5878-4467
Dr. Sci. (Med.), Professor, Leading Researcher, Scientific and Clinical Department of Dermatology
Russian Federation, YekaterinburgMuza M. Kokhan
Ural Research Institute of Dermatovenereology and Immunopathology
Author for correspondence.
Email: mkokhan@yandex.ru
ORCID iD: 0000-0001-6353-6644
SPIN-code: 3470-9306
Dr. Sci. (Med.), Professor, Head of the Scientific and Clinical Department of Dermatology
Russian Federation, YekaterinburgReferences
- Олисова О.Ю., Бакулев А.Л., Кохан М.М. и др. К вопросу о классификации псориаза. 2021;97(5):18–25. [Olisova O.Yu., Bakulev A.L., Kokhan M.M., et al. Revisiting the question of psoriasis classification. 2021;97(5):18–25. (In Russ.)]. https://doi.org/10.25208/vdv1267
- Кубанов А.А., Богданова Е.В. Дермато-венерология в Российской Федерации: итоги 2023 г. Вестник дерматологии и венерологии. 2024;100(4):9–24. [Kubanov А.А., Bogdanova E.V. Dermatovenereology in the Russian Federation: results of 2023. Vestnik Dermatologii i Venerologii. 2024;100(4):9–24. (In Russ.)]. https://dx.doi.org/https://doi.org/10.25208/vdv16795
- Кунгуров Н.В., Филимонкова Н.Н., Тузанкина И.А. Псориатическая болезнь. Екатеринбург, 2002. 193 с. [Kungurov N.V., Filimonkova N.N., Tuzankina I.A. Psoriatic disease. Ekaterinburg, 2002. 193 p. (In Russ.)].
- Guilhou J.-J. Immunopathogenesis of psoriasis: news in an old concept. Dermatology. 1998;197:310–312.
- Israel L., Mellett M. Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease. Front Immunol. 2018;9:2239. https://dx.doi.org/10.3389/fimmu.2018.02239
- Mahil S.K., Twelves S., Farkas K., et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136:2251–2259. https://dx.doi.org/10.1016/j.jid.2016.06.618
- Cai Y., Xue F., Quan C., et al. A critical role of the IL-1β–IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 2019;139:146–156. https://dx.doi.org/10.1016/j.jid.2018.07.025
- Mikhaylov D., Hashim P.W., Nektalova T., Goldenberg G. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits. J Clin Aesthet Dermatol. 2019;12(6):46–54.
- Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320. https://dx.doi.org/10.1046/j.1365-2230.2001.00832.x
- Клинические рекомендации «Псориаз». Минздрав, 2023. [Clinical guidelines ‘Psoriasis’. RODVK 2023. (In Russ.)]. URL: https://cr.minzdrav.gov.ru
- Олисова О.Ю., Теплюк Н.П., Пинегин В.Б. Современные методы лечения псориаза. Русский медицинский журнал. 2015;9:483–484. [Olisova O.Yu., Teplyuk N.P., Pinegin V.B. Modern methods of psoriasis treatment. Russian Medical Journal. 2015;9:483–484. (In Russ.)].
- Makino T., Okajima K., Uebayashi R., Ohtake N., et al. 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11β-hydroxysteroid dehydrogenase 2. Pharmacol Exp Ther. 2012;342(2):297–304. https://dx.doi.org/10.1124/jpet.111.190009
- Круглова Л.С. Турбовская С.Н. Кальципотриол – современные возможности длительного контроля над псориазом в течение года. Клиническая дерматология и венерология. 2017;16(2):53–59. [Kruglova L.S., Turbovskaya S.N. Calcipotriol – modern possibilities of long-term control over psoriasis during the year. Clinical dermatology and venereology. 2017;16(2):53–59. (In Russ.)]. https://dx.doi.org/10.17116/klinderma201716253-59
- Nazari S., Rameshrad M., Hosseinzadeh H. Toxicological effects of Glycyrrhiza glabra (Licorice): a review. Phytother Res. 2017;31(11):1635–1650. https://dx.doi.org/10.1002/ptr.5893
- Isbrucker R.A., Burdock G.A., Isbrucker R.A., Burdock G.A. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006;46(3):167–192. https://dx.doi.org/10.1016/j.yrtph.2006.06.002
- Zhang Y., Wang Q., Sun S., Jiang L. The therapeutic effect of glycyrrhizic acid compound ointment on imiquimod-induced psoriasis-like disease in mice. PLoS One. 2023;18(8):e0290637. https://dx.doi.org/10.1371/journal.pone.0290637
- Piquero-Casals J., Morgado-Carrasco D., Granger C., et al. Urea in dermatology: a review of its emollient, moisturizing, keratolytic, skin barrier enhancing and antimicrobial properties. Dermatol Ther (Heidelb). 2021;11(6):1905–1915. https://dx.doi.org/10.1007/s13555-021-00611-y
- Ковалева Ю.С., Кокина О.А., Ведлер А.А., Кожевникова П.Е. Возможности применения мочевины в дерматологии. Клиническая дерматология и венерология. 2020;19(5):685–689. [Kovaleva Ju.S., Kokina O.A., Vedler A.A., Kozhevnikova P.E. Urea applications in dermatology. Russian Journal of Clinical Dermatology and Venereology. 2020;19(5):685–689. (In Russ.)].
- Celleno L. Topical urea in skincare: a review. Dermatol Ther. 2018;31(6):e12690. doi: 10.1111/dth.12690
- Спиричев В.Б. Витамины, витаминоподобные и минеральные вещества: Справочник. М.: МЦФЭР, 2004. 240 с. [Spirichev V.B. Vitamins, vitamin-like and mineral substances: Handbook. M.: MCFER, 2004. 240 p. (In Russ.)].
- van Rosendal S.P., Osborne M.A., Fassett R.G., Coombes J.S. Guidelines for glycerol use in hyperhydration and rehydration associated with exercise. Sports Med. 2010;40(2):113–119. https://dx.doi.org/10.2165/11530760-000000000-00000
Supplementary files
